Ratings Surperformance

Trader
Investor
Global
Quality
-
ESG MSCI
BB

Ratings ESG MSCI

Ratings Pacira BioSciences, Inc.: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Pacira BioSciences, Inc.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Pacira BioSciences, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.4 times its estimated earnings per share for the ongoing year.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Rating Financials

Pacira BioSciences, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Pacira BioSciences, Inc. SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Pacira BioSciences, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Pacira BioSciences, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Pacira BioSciences, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1B
BB
-
1,060B
A
619B
BBB
438B
AA
-
333B
AA
282B
AAA
267B
A
218B
A
196B
A
161B
AA
Average 357.49B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. PCRX Stock
  4. Ratings Pacira BioSciences, Inc.